Abstract | AIMS: METHODS: Randomized double-blind placebo-controlled trial consisting of three 10-day phases: baseline (phase 1), treatment with rifaximin 400 mg b.i.d. or placebo (phase 2), and post-treatment period (phase 3). Primary efficacy variable was subjective global symptom relief at the end of each phase. A symptom score was calculated from a symptom diary. Lactulose H2-breath test (LHBT) was performed at baseline and end of study. RESULTS: One hundred and twenty-four patients were enrolled (63 rifaximin and 61 placebo). Baseline characteristics were comparable and none had an abnormal baseline LHBT. Rome II criteria were met in 58.7% and 54.1%, respectively. At the end of phase 2, there was a significant difference in global symptom relief with rifaximin versus placebo (41.3% vs 22.9%, p = 0.03). This improvement was maintained at the end of phase 3 (28.6% vs 11.5%, p = 0.02). Mean cumulative and bloating-specific scores dropped significantly in the rifaximin group (p < 0.05). Among patients with IBS, a favorable response to rifaximin was noted (40.5% vs 18.2%; p = 0.04) persisting by the end of phase 3 (27% vs 9.1%; p = 0.05). H2-breath excretion dropped significantly among rifaximin responders and correlated with improvement in bloating and overall symptom scores (p = 0.01). No adverse events were reported. CONCLUSIONS:
Rifaximin is a safe and effective treatment for abdominal bloating and flatulence, including in IBS patients. Symptom improvement correlates with reduction in H2-breath excretion. Future trials are needed to examine the efficacy of long-term or cyclic rifaximin in functional colonic disorders.
|
Authors | Ala I Sharara, Elie Aoun, Heitham Abdul-Baki, Rawad Mounzer, Shafik Sidani, Ihab Elhajj |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 101
Issue 2
Pg. 326-33
(Feb 2006)
ISSN: 0002-9270 [Print] United States |
PMID | 16454838
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Gastrointestinal Agents
- Rifamycins
- Lactulose
- Hydrogen
- Rifaximin
|
Topics |
- Adult
- Breath Tests
- Double-Blind Method
- Female
- Flatulence
(diagnosis, drug therapy)
- Follow-Up Studies
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Hydrogen
(analysis)
- Lactulose
- Male
- Rifamycins
(therapeutic use)
- Rifaximin
- Treatment Outcome
|